Strategy
When a person becomes blind, the lifetime cost to the healthcare system can be up to £237,0001. This is a preventable cost in the case of diabetic retinopathy. Set against the backdrop of a burgeoning diabetic population, iGrading is a powerful ally in diabetic retinopathy prevention and delivery against broader diabetes targets. It supports the strategic and long term approach of a world class commissioning programme.
While all of this translates into tangible time and cost savings against existing programmes, the system is so flexible it can be deployed in situations where screening infrastructure is in the early stages of developmentdevelopment – delivering cost-effective results on the tightest of timescales.